Purdue execs plead guilty to OxyContin fraud
According to The New York Times, the parent company of Purdue Pharma has agreed to pay more than $600 million in fines to resolve claims that it fraudulently marketed OxyContin as a painkiller less prone to abuse with fewer side effects. In addition, three current and former executives of Purdue, including its president, have agreed to plead guilty to criminal charges of misbranding the drug. Federal officials told The New York Times that Purdue executives admitted that sales people were allowed to come up with their own fake scientific charts to back up false assertions that the drug was less prone to abuse than competitors on the market. Company President Michael Friedman has agreed to pay a $19 million fine, attorney Howard Udell will pay $8 million and former medical director Dr. Paul Goldenheim will pay $7.5 million.
- read the New York Times report on the plea deal
Related Articles:
RFID tracking system goes live for painkiller. Report
Purdue slashes work force as generic OxyContin gets green light. Report
Be the first to comment Rate it:
Comments
By dcpsychcenter | Posted 12:34pm | May 13, 2008
Very interesting article. It's terrible how people with chronic pain are forced to cheat the system to get the medication they need. Here's another article on OxyContin abuse, and how the drug company's are claiming they provide pain relief for a lot longer then they actually do. OxyContin Abuse : Alen J. Salerian, M.D.
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends